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INTRODUCTION 
Dendrimers are the new artificial macromolecules which 
have the structure like a tree. They are class of well 
defined hyperbranched synthetic polymer systems, 
which can be conjugated to various chemical species, 
such as detection agents, imaging agents, targeting 
components, biomolecules, pharmaceutical/therapeutic 
agents, radio ligands, affinity ligands, for various 
bioanalytical applications.  The term “Dendrimer” arise 
from two Greek word; “Dendron” meaning tree and 
“Meros” meaning part. A typical dendrimer structure 
consists of three basic components: a multi-functional 
central core moiety where other molecules can be 
trapped 
1, 2
, branched units that emanates from the 
central core and external capping-groups. The highly 
regular branching units are organized in layers called 
“generations”, and represent the repeating monomer unit 
of these synthetic macromolecules
3
. Therefore, 
dendrimers can be synthesized from simple branched 
monomer units, in a precise and controlled fashion from 
trunk to branch and to leaf “surface groups”. 
The three-dimensional structure of dendrimers gives 
them a variety of unique properties, such as nanoscaled 
globular shape, well-defined functional groups at the 
periphery, hydrophobic or hydrophilic cavities in the 
interior and extremely low polydispersity 
4
, and thus a 
wide range of potential applications. 
They are nanoparticles and so has advantages over 
microparticles or others due to its small size, easy uptake 
by cells (through endocytosis) and thus brings drug 
“bound” to dendrimers into the cell 4, 5. They are 
branched macromolecules have a central core unit 
having a high degree of molecular uniformity, narrow 
molecular weight, distribution, specific size and shape 
characteristics, and a highly- functionalized, terminal 
surface. The manufacturing process is a series of 
repetitive steps generating shells, starting with a central 
initiator core. Each subsequent shell represents a new 
"generation" of polymer with a larger molecular 
diameter, twice the number of reactive surface sites, and 
approximately double the molecular weight of the 
preceding generation.  
The precise control over the distribution of drugs is 
highly valuable to abolish the typical drawbacks of 
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traditional medicine. In recent years, improved 
pharmacokinetics, biodistribution and controlled release 
of the drug to the specific targeted site has been 
achieved with polymer based drug delivery
6
 Unlike 
traditional polymers, dendrimers have received 
considerable attention in biological applications due to 
their high water solubility,
7
 biocompatibility,
8
 
polyvalency
9
 and precise molecular weight.
3
 These 
features make them an ideal carrier for drug delivery and 
targeting applications. For investigating dendrimers as 
drug delivery vehicles, their biopermeability across the 
biological membranes should be considered. In this 
review, we report on the noteworthy scientific advances 
and most recent literature, dealing various application of 
dendrimer in the field of drug delivery. 
 
 
Figure 1: Schematic representation of the Dendrimer Structure. Adopted from reference 
10
 
 
WHAT MAKES DENDRIMERS SPECIAL IN DRUG DELIVERY 
Dendrimers are dentritic polymers that have very well-
defined nanostructures and high level control over its 
size, branching density and surface functionality. They 
are useful nanoscale carriers for drug and gene delivery. 
Both hydrophilic and phrophobic drug molecules can be 
formulated with dendrimers. They have been applied in 
intravenous, oral, pulmonary, nasal, ocular, and 
transdermal drug delivery systems. 
Dendrimers have shown enormous potential as 
nanocarrier/delivery systems because they can cross cell 
barriers by both paracellular and transcellular pathways. 
The ability to statistically modify and optimize the 
number and/or ratio of dendrimer surface groups that 
influence biodistribution, receptor-mediated targeting, 
therapy dosage or controlled release of drugs from the 
dendrimer interior.  
The three-dimensional structure of dendrimers gives 
them a variety of unique properties, such as nanoscaled 
globular shape, well-defined functional groups at the 
periphery, hydrophobic or hydrophilic cavities in the 
interior and extremely low polydispersity 
11
, and thus a 
wide range of potential applications. For example, most 
dendrimers have globular structures with molecular 
diameters less than 10 nm, which can be modulated by 
varying dendrimer generations. 
This property gives dendrimers similar sizes and shapes 
as specific proteins and other biomolecules and thereby 
makes them perfect as biomimics 
12
. Also, the highly 
regular branching pattern of dendrimers imbues these 
dendritic architectures with well-defined numbers of 
periphery functional groups, providing opportunities for 
the presence of drug molecules, targeting moieties, and 
solubilizing groups on the surface in a multivalent 
fashion 
13, 14
. Moreover, hydrophobic and hydrophilic 
cavities in the interior of dendrimers make them useful 
candidates as unimolecular micelles for the 
encapsulation of guest molecules, especially drugs 
15-16
. 
Finally, the low polydispersity of dendrimers assures the 
reproducibility of biodistribution of polymeric prodrugs 
using them as scaffolds 
17-18
. 
Nanoparticles having a size in the range 1–10 nm have 
the capacity to diffuse into tumor cells. This helps to 
overcome limitations relating to chemotherapy using 
free drug such as poor in vivo/in vitro correlation and 
overcome other possible resistances offered by tumors. 
Dendrimers are one of the most useful non-viral gene 
delivery systems. Their ability to transfect cells without 
inducing toxicity and be tuned for stimuli-induced gene 
delivery confers a great advantage over other gene 
delivery vectors for use in vivo. 
The well-defined hyperbranched structure of dendrimers 
has motivated chemists to explore the possibility for 
mimicking protein functions with dendritic 
macromolecules, such as O2-carrying haemoproteins 
and coenzyme B12. Thus, dendrimers can be tuned for: 
(i) be stimuli-responsive nanocarriers, (ii) include 
moleculartags, (iii) possess high payload efficiency, (iv) 
decrease dosage requirements as well as re-dosage 
frequency and (v) target delivery and minimize drug 
migration, thus suppressing secondary effects during 
drug treatment. 
The interesting nanoscale architecture of dendrimers 
confers several structural benefits over linear polymers, 
larger nanoparticles and liposomes. Such advantages 
include rapid cellular entry, reduced macrophage uptake, 
targetability and more facile passage across biological 
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barriers by transcytosis
19
. In comparison to linear 
polymers, dendrimers are multivalent owing to the 
presence of high multiplicities of reactive surface end 
groups, making them ideal drug carriers with higher 
drug payload capacities
20
. Encapsulation of drugs in 
PEGylated dendrimers can lead to enhanced permeation 
and retention (EPR) of the drug. 
They can be synthesized and designed for specific 
applications. Due to their feasible topology, 
functionality and dimensions, they are ideal drug 
delivery systems; and also, their size is very close to 
various important biological polymers and assemblies 
such as DNA and proteins which are physiologically 
ideal
.21-22
 
The covalent attachment of drugs to the surface groups 
of dendrimers through hydrolysable or biodegradable 
linkages enhances the pharmacological properties of the 
drug and offers the opportunity for a greater control over 
drug release. 
Dendrimers are capable of improving the solubility, 
biodistribution, and efficacy of a number of therapeutics 
as well as being used as imaging and diagnostic 
molecules in animal models bearing brain tumors. These 
therapeutics can be conjugated to the surface via tumor-
labile (pH sensitive) linkers or encapsulated 
noncovalently into the structure via electrostatics. 
 
Table 1: Summary of the advantages of Dendrimers 
 Improved bioavailability 
 Overcoming of cellular barriers 
 Cite specific Drug delivery 
 Controlled drug release 
 Better patient compliance 
 Increased solubility, stability, and permeability of drugs 
 Reduced macrophage uptake 
 Facile passage across biological barriers by transcytosis 
 Improved delivery efficiency 
 The capability to deliver a variety of drugs 
 Viral diagnosis 
 Ability to maintain drug levels in a 
therapeutically desirable range 
 Increased half-life 
 Increased drug retention and providing extended 
therapeutic effects (e.g. Ocular drug delivery) 
 Reduced side effects by targeted delivery 
 Low toxicity and low immunogenicity 
 High uniformity and purity 
 Rapid cellular entry 
 
 
MECHANISMS OF DRUG DELIVERY VIA 
DENDRIMERS:  
Dendrimers are particularly attractive as they offer a 
high drug-loading capacity. Due to the well defined 3D 
structure and many surface functional groups, drug 
molecules can be loaded both in the interior of the 
dendrimers as well as attached to the surface groups. 
Dendrimers can function as drug carriers either by 
encapsulating drugs within the dendritic structure or by 
interacting with drugs at their terminal functional 
groups via electrostatic or covalent bonds forming 
prodrug. Encapsulation of drugs and dendrimer –drug 
conjugates
23-24 
  are two main methods of dendrimer 
drug delivery. 
1. Non-covalent Encapsulation of Drugs / Host –
Guest Relation 
Incorporation of small organic molecules may be a 
result of non‑bonding interactions with specific groups 
within dendrimer, i.e. just physical entrapment 
Encapsulation of drugs uses the satiric bulk of the 
exterior of the dendrimer or Interactions between the 
dendrimer and drug to trap the drug inside the 
dendrimer. Such a system can be used to encapsulate 
drugs and provide controlled delivery. Initial studies of 
dendrimer as potential delivery systems focused on 
their use as unimolecular micelles and ‘dendritic 
boxes’ for the noncovalent encapsulation of drug 
molecules. For example, in early studies, DNA was 
complexed with PAMAM dendrimers for gene 
delivery applications, and hydrophobic drugs and dye 
molecules were incorporated into various dendrimer 
cores. An advantage of using dendritic unimolecular 
micelles rather than conventional polymeric micelles is 
that the micellar structure is maintained at all 
concentrations because the hydrophobic segments are 
covalently connected
25
.  
Dendrimers can be used as dendritic boxes and 
unimolecular micelles (dendrimer‑drug networks) for 
the incorporation of hydrophobic/hydrophilic 
molecules by host guest interactions inside their empty 
cavities (nanoscale containers) present around core.
26-27
 
Jansen et al. were the first to entrap the rose bengal dye 
molecules in PPI dendrimers by using 
tert‑butyloxycarbonyl (t‑Boc) groups and led to the 
production of stable dendritic box that possess the 
bulky amino groups on the dendrimer surface.
28
 
The dendritic unimolecular micelles contain the 
hydrophobic cores surrounded by hydrophilic shells 
and they offer an advantage over conventional 
polymeric micelles such that the micellar structure is 
maintained at all the concentrations because the 
hydrophobic segments are covalently connected. 
2. Covalent Dendrimer–Drug Conjugates 
Alternatively, the exploitation of well‑defined 
multivalent aspect of dendrimers allows the attachment 
of drug molecules to its periphery that result in 
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complex formation. The resultant complexes are 
formed either due to the electrostatic interactions 
between the drug and dendrimer or conjugation of the 
drug to dendrimer molecule. Through electrostatic 
interactions, various ionizable drugs form complexes 
with the large number of ionizable terminal surface 
groups of dendrimers.
29
 
In dendrimer–drug conjugates, the drug is attached 
through a covalent bond either directly or via a 
linker/spacer to the surface groups of a dendrimer. 
Dendrimers have been conjugated to various 
biologically active molecules such as drugs, 
antibodies, sugar moieties and lipids .The drug loading 
can be tuned by varying the generation number of the 
dendrimer, and release of the drug can be controlled by 
incorporating degradable linkages between the drug 
and dendrimer. Moreover, the drugs can be covalently 
conjugated to dendrimers through some spacers that 
may include PEG, p‑amino benzoic acid, p‑amino 
hippuric acid and lauryl chains etc., or biodegradable 
linkages such as amide or ester bonds.  
 
Figure 2: Different types of drug‑dendrimer 
interactions. Adopted from reference 
10
 
 
APPLICATION OF DENDRIMERS IN DRUG 
DELIVERY 
Over the past 30 years greater attention has been 
focused on development of controlled and sustained 
drug delivery systems. Amongst the extensive research 
has been carried in designing of polymeric drug 
delivery systems
30
. 
The development of dendrimer based efficient drug 
delivery systems has attracted a great deal of attention 
over the last few years. Unlike traditional polymers, 
dendrimers can be obtained in precise molecular 
weights even at high generations, which as previously 
highlighted can provide a reproducible 
pharmacokinetic behavior. This feature makes them 
ideal candidates for drug delivery applications. 
However, efficient drug delivery systems should meet 
other criteria, such as: (i) structural control over the 
size and shape of drug or imaging-agent cargo-space; 
(ii) biocompatibility, non-toxic polymer/pendant 
functionality; (iii) precise, nanoscale-container and/or 
scaffolding properties with high drug-loading capacity; 
(iv) well-defined scaffolding and/or surface modifiable 
functionality for cell specific targeting moieties; (v) 
lack of immunogenicity; (vi) appropriate cellular 
adhesion and internalization, (vii) adequate bio-
elimination or biodegradation; (viii) controlled or 
stimuli-responsive drug release features; (ix) molecular 
level isolation and protection of the drug against 
inactivation during transit to target cells; (x) minimal 
non-specific cellular and blood–protein binding 
properties; (xi) ease of consistent, reproducible, 
clinical grade synthesis. 
 
Figure 3: Various application of dendrimers in drug 
delivery 
1. Dendrimers in CNS Drug Delivery 
The brain is a challenging organ for drug delivery. 
First, the incidence of degenerative diseases in the 
brain will increase with the aging population. 
Secondly, the blood brain barrier (BBB) is well-known 
as the best gatekeeper in the body toward exogenous 
substances. All the current therapeutic strategies are 
not efficient in treating disorders related to the CNS
31
. 
Delivery of therapeutics to the brain is challenging 
because many organic molecules have inadequate 
aqueous solubility and limited bioavailability. 
As the vast majority of potential CNS compounds have 
limited brain uptake, they may benefit from the use of 
advanced delivery systems in order to cross the BBB. 
The drug is encapsulated in, or associated to the 
particle, thereby masking its physiochemical 
characteristics
32.
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Table 2: Rational design of dendrimers for CNS Drug Delivery 
Dendrimers can offer many advantages over 
conventional drug delivery. They: 
 improve the delivery of therapeutics to the CNS by 
bypassing or crossing the BBB 
 protect the drug from premature degradation; 
 enhance absorption of the drugs into a selected tissue 
(for example, solid tumour); 
 control the pharmacokinetic and drug tissue distribution 
profile; 
 have ability to maintain drug levels in a therapeutically 
desirable range 
increased solubility, stability, and permeability of 
drugs, 
 have low toxicity and low immunogenicity 
 For rapid and effective clinical translation, the 
Dendrimer carrier should: 
 be made from a material that is biocompatible, well 
characterized, and easily functionalized; 
 not only transport across the BBB but also target 
specific cells 
 pass the membrane and deliver the drug held in its 
interior  
 Have potential to overcome inadequate aqueous 
solubility and limited bioavailability of drugs 
 Require deeper toxicological studies 
 Engineered properly in order to enable their long 
term use without the accumulation of adverse 
effects 
 
BBB is essential for maintaining a healthy brain; it 
impedes efforts to deliver therapeutic agents into the 
brain. The poor permeability of various drugs as well as 
delivery systems across the BBB is primarily due to 
tight junctions, lack of capillary fenestrations and pres- 
ence of efflux transporters. The BBB can reportedly 
block more than 98% of CNS drugs
33
. Due to the 
ineffectiveness of conventional drug therapies, finding 
ways to deliver therapeutic drugs to the CNS safely and 
effectively is essential. The development of novel 
strategies that could overcome the obstacles of brain 
drug delivery is essential. The application of 
nanoscience to CNS disorders is an active area of 
research.  
Nanomedicine has shown great potential for the 
treatment of many CNS diseases. Nanomedicine is the 
biomedical and pharmaceutical application of 
nanotechnology for making nanocarriers of therapeutics 
and imaging agents, nanoelectronic biosensors, and 
nanodevices with nanostructures. A number of 
nanocarrier delivery systems, including dendrimers, 
liposomes,  polymeric micelles,  linear polymers, 
quantum dots, and iron oxide Nanoparticles have been 
developed and have demonstrated promising properties 
in CNS drug deliver
34
.  
Among these, much attention has been paid to 
dendrimers because of their advantages, which include 
(1) the ability to maintain drug levels in a 
therapeutically desirable range, (2) increased half-life, 
(3) increased solubility, stability, and permeability of 
drugs, (4) the capability to deliver a variety of drugs, (5) 
reduced macrophage uptake, (6) targeting ability, (7) 
facile passage across biological barriers by transcytosis, 
(8) rapid cellular entry, (9) improved delivery 
efficiency,  (10) reduced side effects by targeted 
delivery, (11) low toxicity and low immunogenicity, and 
(12) high uniformity and purity.
19, 35-36 
The presence of a large number of surface groups 
provides opportunity to conjugate ligands not only for 
transport across the BBB but also for target- ing specific 
cells, such as tumors. Dendrimers can be prepared with 
specific surface modifications that enable the 
dendrimers to gain entry through a membrane while 
holding a molecule that cannot pass on its own. Once 
the dendrimer passes the membrane, it can deliver the 
drug held in its interior. 
The mechanism of uptake and toxicity to the BBB has 
not been extensively studied. A detailed characterization 
of dendrimer toxicity is important for the design and use 
of dendrimers in brain drug delivery. Toxicity of both 
the functional group and generation of the dendrimer 
must be taken into consideration. PAMAM dendrimers 
have been shown to be haemolytic and cytotoxic, with 
toxicity tending to be higher for cationic PAMAM 
dendrimers and to increase with generation
8,37
. 
Heather et al evaluated the potential toxicity of 
biotinylated G4 PAMAM dendrimer conjugates. Biotin 
is an important molecule used in several metabolic path- 
ways and belongs to a family of molecules that have 
been shown to cross the BBB. The biophysical 
interactions of biotinylated G4 PAMAM conjugates and 
G4 PAMAMs with lipid model membranes were 
evaluated using Langmuir Blodgett monolayer 
techniques and atomic force microscopy (AFM). Results 
were correlated with cellular toxicity measurements 
using endothelial cell culture models of the BBB. This 
work reports the first analysis of PAMAM dendrimers 
using this combined approach. The results provide 
important insights into strategies for developing 
nanoparticle systems for brain drug delivery
38
. 
Delivery of therapeutics to the brain is challenging 
because many organic molecules have inadequate 
aqueous solubility and limited bioavailability. Katare et 
al investigated the efficiency of a dendrimer-based 
formulation of a poorly aqueous soluble drug, 
haloperidol, in targeting the brain via intranasal and 
intraperitoneal administration. Aqueous solubility of 
haloperidol was increased by more than 100-fold in the 
developed formulation. Formulation was assessed via 
different routes of administration for behavioral 
(cataleptic and locomotor) responses, and for 
haloperidol distribution in plasma and brain tissues. 
Dendrimer-based formulation showed significantly 
higher distribution of haloperidol in the brain and 
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plasma compared to a control formulation of haloperidol 
administered via intraperitoneal injection. Additionally, 
6.7 times lower doses of the dendrimer−haloperidol 
formulation administered via the intranasal route 
produced behavioral responses that were comparable to 
those induced by haloperidol formulations administered 
via intraperitoneal injection. This study demonstrates the 
potential of dendrimer in improving the delivery of 
water insoluble drugs to brain 
39
. 
Polyesters based dendrimers have been proposed for 
CNS regenerative medicine. Dhanikula et al. 
40-41
 
suggested the use of polyether-copolyester (PEPE) 
dendrimers conjugated with d-glucosamine, and loaded 
with methotrexate (MTX) in order to allow a better 
delivery across the BBB. The results revealed that the 
efficacy of MTX-loaded dendrimers was established 
against U87 MG and U 343 MGa cells (two glioma cell 
lines). In vitro studies revealed that glucosylated 
dendrimers were internalized by endocytosis in 
significantly higher amounts than non-glucosylated 
dendrimers by both the cell lines. Moreover, the amount 
of MTX-transported across an in vitro model of the 
BBB was three to five times more after loading in the 
dendrimers, which indicates that glucosylation further 
increased the cumulative permeation of dendrimers 
across BBB, and hence increased the amount of MTX 
available across it. This work evaluated a different set of 
dendrimers, as well as different strategy, for potential 
use delivery across the BBB. However, it should be 
considered with caution, as only in vitro models were 
used, and the in vivo proof of concept is yet to be 
demonstrated. 
Prieto et al. 
42
 investigated the cytotoxicity of 
sulfadiazine complexed with fourth-generation 
PAMAM dendrimers. Cell culture studies using 
fibroblasts (Vero cells) and macrophages (J-774 cells) 
revealed that the dendrimeric sulfadiazine complexes 
did not affect membrane integrity at low concentrations 
(0.031M). Moreover, cytotoxicity tests using human 
intestinal adenocarcinoma cell line (Caco-2 cells) 
showed that dendrimeric sulfadiazine did not reduce 
viability of Caco-2 cells over the tested concentrations 
as compared to that for PAMAM (G4). Remarkably, the 
in vivo study has shown that brain and muscle of Wistar 
rats are the main targets of intravenous administration of 
dendrimeric sulfadiazine, which can be advantageous 
for drug delivery applications directed to central nervous 
system. 
However, challenges still exist regarding the deeper 
toxicological studies, specific targeting, and noninvasive 
alternative drug administration methods. The ultimate 
goal of dendrimer-mediated CNS drug-delivery systems 
is to engineer the dendrimers to be safe and to enable 
their longterm use without the accumulation of adverse 
effects. 
2. Dendrimers in Oral Drug Delivery 
The oral route of drug delivery in general is considered 
the favourite means of drug administration
43, 44
. Despite 
of tremendous innovations in drug delivery, the oral 
route remains the preferred route for administration of 
therapeutic agents because of accurate                        
dosage, low cost therapy, self medication, non invasive 
method and ease of administration leading to high level 
of patient compliance.
45
 
Dendrimers are suitable candidate in oral drug delivery 
because dendrimers loosened the tight junctions of 
epithelial layer and thus an improvement in the 
absorption of small molecular weight drugs was 
achieved 
46
. The transepithelial transport and toxicity of 
polyamidoamine dendrimers as carriers for oral drug 
delivery has been reviewed by Sadekar and Ghandehari 
47
 
Kolhe et al. 
48
 demonstrated that ibuprofen 
predominantly forms a complex with PAMAM (G3 and 
G4) dendrimers because of the ionic interaction between 
the –NH2 end groups and the carboxyl group of 
ibuprofen. In this work, they demonstrated that the in 
vitro release of ibuprofen from drug–dendrimer complex 
is appreciably slower compared to pure ibuprofen. 
Moreover, the FITC-labeled dendrimer-complexed drug 
enters human lung epithelial carcinoma A549 cells 
much faster than pure drug, suggesting that dendrimers 
may be able to carry the complexed drug inside cells 
efficiently. 
In another work Kolhe et al 
13
 synthesized a fourth-
generation PAMAM (PAMAM-OH) dendrimer 
covalently linked to ibuprofen using 
dicyclohexylcarbodiimide (DCC) as a coupling agent. A 
high payload nanocarrier was obtained; 
49
 molecules of 
ibuprofen were covalently conjugated to one molecule 
of PAMAM-OH (G4) dendrimer. FITC-labeled 
dendrimer–drug conjugate nanoparticles internalization 
was evaluated in vitro once using A549 cells. The 
pharmacological activity of the dendrimer–ibuprofen 
conjugate was compared to pure ibuprofen at various 
time points by measuring the suppression of 
prostaglandin E2. Results demonstrated the high 
internalization efficiency of the FITC-labeled 
dendrimer–drug conjugate and superior therapeutic 
activity due to faster prostaglandin E2 suppression. 
Thus, the results suggest that the dendrimer–ibuprofen 
conjugate improve the drug efficacy by enhanced 
cellular delivery, and may produce a rapid 
pharmacological response. 
3. Dendrimers in Nasal Drug Delivery 
Developing a noninvasive and safe alternative drug 
administration to substitute i.v. or i.t. administration is 
highly preferred because of their associated poor patient 
compliance
 50
. Transmucosal routes of drug delivery 
(i.e., the mucosal linings of the nasal, rectal, vagina, 
ocular and oral cavity) offer distinct advantages over 
peroral administration for systemic drug delivery. These 
advantages includes possible bypass of the first pass 
effect, avoidance of pre-systemic elimination of gastro 
intestinal tract and depending on the particular drug.
51 
Nasal administration offers an interesting alternative for 
achieving systemic drug effects to the parenteral route, 
which can be inconvenient or oral administration, which 
can result in unacceptably low bioavailabilities.
52
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Intranasal (IN) delivery is distinguished among the 
various strategies currently available for drug targeting. 
It is noninvasive and reduces the exposure of nontarget 
sites to therapeutic substances, thus increasing 
efficiency and safety of drug delivery. Drug molecules 
can be targeted to the brain from the nasal cavity 
through the olfactory nerve pathway and trigeminal 
nerve pathway, therein bypassing the BBB. In addition 
to this, drug molecules can be systemically absorbed 
from the nasal cavity and can subsequently permeate the 
BBB if the drug molecules have sufficient 
lipophilicity.
53
 IN drug delivery is advantageous for 
water-soluble molecules, particularly biomolecules like 
proteins, which have poor bioavailability in brain tissues 
through oral or parenteral routes.
54,55
 However, most 
small molecules that are used for therapy of CNS 
disorders have limited aqueous solubility. As such, they 
need to be formulated in nanoparticles or emulsions, 
solubilized using micellar solubilization or 
complexation with dextrans in order to be delivered to 
the brain via the IN route.
53,56
 Although use of 
nanoparticles has been reported to improve the delivery 
of drugs to the brain via the IN route in several 
studies,
57-60
 transport of large sized particles, especially 
larger than 200 nm, is not efficient due to poor 
paracellular and intracellular transport.
58
 
Among various drug delivery systems, dendrimers due 
to their small size (less than 10 nm) are likely to have 
more efficient paracellular and transcellular transport 
across the BBB,
 58
 which makes them ideal carriers for 
targeting water insoluble drugs to the brain via IN 
administration. Dendrimers are discrete 
nanostructures/nanoparticles which are synthesized 
beginning with a core, and grown in concentric layers to 
produce stepwise increases in size.  
Dendrimers have been reported to enhance the aqueous 
solubility of drugs by forming a complex with them
61
 
which would provide a high concentration of diffusible 
drug at the nasal area. The dendrimers can be selected so 
as to a have positive charge on the surface that would 
also lead to increased transport of drugs to the brain as 
positively charged nanoparticles have been reported to 
have increased association with mucus as well as greater 
cell uptake.
 58
 
In Nasal drug delivery Dendrimers can offer many 
advantages over conventional drug delivery. They: 
 Enhance the aqueous solubility of drugs 
 Increased transport of drugs to the brain 
 Have more efficient paracellular and transcellular 
transport across the BBB,  which makes them ideal 
carriers for targeting water insoluble drugs to the 
brain 
Intranasal delivery of the water-soluble radiolabeled 
siRNA−dendrimer complexes (dendriplexes) 
incorporated into in situ forming mucoadhesive gels 
shows increased radioactivity in the brain as compared 
to that obtained following IN delivery of si RNA 
incorporated in the similar mucoadhesive gels.
62
 
However, to date there is no report on using dendrimers 
for targeting water-insoluble drugs to the brain via 
intranasal administration and how this route of 
administration compares with intraperitoneal 
administration of the same formulations. 
Polyamidoamine (PAMAM) dendrimer has draws 
attention for nose-to-brain targeting. These dendrimers 
are repetitive branches that grow from a core. Many 
versatile molecules can be attached to their surface. Kim 
et al. connected an arginine onto the surface of a 
PAMAM dendrimer 
63
. This resulted in nanoparticles 
with a size of 188.7 ± 1.9 nm and a charge of +22.3 mV. 
Small interference RNA (siRNA) targeting against the 
high mobility group box 1 protein (HMGB1) was 
electrostatically attached onto the nanoparticles. 
HMGB1 is released by dying cells and acts as a danger 
signal, thereby aggravating the damage of a stroke or 
other neurotoxic insults. Upon intranasal administration, 
they observed a wide distribution of the construct into 
the brain, including the hypothalamus, the amygdala, the 
cerebral cortex, and the striatum. Moreover, the 
localization of the PAMAM dendrimer and the siRNA 
was associated with an efficient knock-down of the 
protein of interest: HMGB1. When a stroke was induced 
into animals, the group that received the intranasal 
administration of the construct had a remarkably 
decreased infarction volume. 
The potential of mucoadhesive gel of dendrimers 
formulations for nose to brain delivery was also 
displayed by Perez et al. 
64
. They coupled radioactive 
siRNA to PAMAM dendrimers to form dendriplexes, 
and formulated these particles into mucoadhesive gels 
containing either 1% (w/w) chitosan or 0.25% (w/w) 
carbopol 974P NFTM. These gels were prepared by 
blending the chitosan or carbopol with 23% (w/w) of 
thermosensible poloxamer to obtain in-situ gelation. 
Such a thermosetting gel has a phase transition below 
the temperature in the nasal cavity (32 °C to 35 °C) and 
above room temperature. Therefore it can be 
administered as a liquid. Different concentrations of the 
different gels were tested and no toxicity was observed. 
Two intranasal doses were necessary to achieve higher 
brain concentrations of radioactivity than achieved by 
intravenous administration of dendriplexes or intranasal 
administration of naked siRNA. 
4. Dendrimers in Gene Delivery 
The ability to transfer genetic material efficiently, into 
the nucleus and cytoplasm of eukaryotic cells may allow 
treatment of a variety of genetic disorders. There are so 
many vectors and physical methods are reported for in 
vivo Gene delivery. 
Commonly two approaches viz. viral and non‑viral 
based are being used to facilitate the gene delivery to 
target cells. Although viral carriers (Synthetic DNA 
delivery systems) can achieve rapid transfection, but 
low efficiency, immunological and oncologic adverse 
effects associated with these vectors has remained a 
topic of concern
65-67
.  
Non‑viral gene delivery vectors offer the usage of 
natural/synthetic molecules or physical forces to transfer 
genetic material to targeted cells. Several advantages 
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such as ease of fabrication, targeting ability, potential 
for repeat administration and low immune response have 
led to the usage of non‑viral vectors preferably for gene 
therapy. 
Dendrimers are one of the most useful non-viral gene 
delivery systems and play a significant role in the 
development of non-viral vectors for gene delivery due 
to their ability to transfect cells without inducing 
toxicity, the high charge density and tunable surface 
functional groups, thus allowing optimal condensation 
and formation of nanostructures with DNA, the so-
called “dendriplexes”. 
Many factors affect the efficiency of non-viral gene 
delivery systems. For successful gene therapy the 
genetic material should be permanently integrated and 
expressed by cells. In this context, Galetti et al.
68
 
demonstrated that antisense oligonucleotides (ONs, 
gene-specific sequences of nucleic acids with 15–25 
bases) directed to LMP1 mRNA, effectively suppressed 
LMP1 gene expression, which plays a key role for 
growth transformation and immortalization of B 
lymphocytes. The efficiency of three cationic carriers on 
the delivery of anti-LMP1-ON to their site of action in 
Epstein Barr virus (EBV)-infected B lymphocytes was 
investigated. Results showed that liposomes, dendrimers 
or transferrin-PLL-conjugated ON were internalized by 
the cells at an extent several fold higher than that of the 
naked oligomers. Using Superfect®, a dendrimeric 
polycation with terminal amine groups, a higher 
intracellular concentration of ON was obtained as 
observed by both cytofluorimetric and confocal 
microscopy analyses. However, there was some 
evidence of toxicity induced by the positively charged 
dendrimers on the lymphocytes’ membranes, and the 
lack of intracellular mRNA-ON duplex formation and of 
LMP1 mRNA degradation indicated a failure of this 
carrier. 
Among various commercially available dendrimers, 
PAMAM dendrimers have received the most attention 
as potential non‑viral gene delivery agents due to their 
cationic nature which enables deoxyribonucleic acid 
(DNA) binding at physiological pH.
69
 
Pandita et al. prepared dendrimer based gene delivery 
vectors taking advantage of the cationic nature and the 
“proton‑sponge” effect of these dendrimers. 
Arginine‑glycine‑aspartic (RGD) nanoclusters were 
formed by conjugation of G5 and G6 PAMAM 
dendrimers with a varying number of peptides 
containing the RGD motif, in view of its targeting 
capabilities. Authors reported that the system wherein 
G6 PAMAM dendrimer was conjugated to eight peptide 
arms enhanced the gene expression in mesenchymal 
stem cells and presented a 2‑fold higher bone 
morphogenetic protein‑2 expression in comparison to 
the G6 native dendrimer.
70
 Various published literature 
suggests that functionalized dendrimers are much less 
toxic than the native dendrimers. Same group 
synthesized a new family of gene delivery vectors 
consisting of G5 PAMAM dendrimer core randomly 
linked to hydrophobic chains (with varying chain length 
and numbers). In vitro studies revealed a remarkable 
capacity of these vectors for internalizing pDNA with 
very low levels of cytotoxicity, being this effect 
positively correlated with the CH2 content present in the 
hydrophobic moiety. The results demonstrated that 
vectors containing the smallest hydrophobic chains 
showed the higher gene expression efficiency.
71
 Further, 
functionalized PAMAM dendrimers exhibited low 
cytotoxicity and receptor‑mediated gene delivery into 
mesenchymal stem cells and transfection efficiencies 
superior to those presented by native dendrimers and by 
partially degraded dendrimers.
72
 
The protection of DNA from in vivo degradation by the 
vectors is another key feature for success in gene 
delivery. Diaz-Mochon et al. 
73
 showed that a hybrid 
combination of PAMAM and peptide dendrimers, the 
so-called peptoid dendrimers, were able to transfect cells 
with higher efficiency than the PAMAM counterpart, 
and were nontoxic. In part, this work supported previous 
findings which demonstrated that combination of 
primary and secondary amines generates a “proton 
sponge” effect, which can facilitate theDNAtransfection 
process, by promoting the release of the plasmid from 
the cytoplasmic lysosome. Thus, efficiency of 
dendrimer/DNA complexes may be favored by 
prolonging the release of plasmid. 
As aforementioned, cationic PAMAM dendrimers have 
proved to efficiently mediate transfection of DNA into a 
variety of mammalian cells, in vitro. However, as 
highlighted, the major drawback of high-generation 
cationic dendrimers is their associated cytotoxicity. 
Anionic dendrimers, on the other hand, have shown no 
cytotoxic effect on cells over a broad range of 
concentrations. Hussain et al.
74
 have reported the 
successful use of ONs conjugated with pentaerythritol-
based anionic dendrimers in inhibiting cancer-cell 
growth. In vitro studies using cancer cells showed that 
ONs-dendrimer conjugates enhance the cellular uptake, 
up to four times as compared to that for naked ONs. 
These data clearly demonstrated that anionic ONs-
dendrimer conjugates may represent attractive 
alternatives to cationic non-viral vectors for the delivery 
of gene silencing ONs. However, it is not known 
whether the system may facilitate the delivery of duplex 
siRNA for gene silencing by RNA interference. 
Vincent et al.
75
 investigated the efficacy in cancer 
therapy of non-viral gene transfer using the anti-
angiogenic angiostatin (Kringle 1–3) and tissue 
inhibitors of metalloproteinases (TIMP) genes. This 
study revealed that it was possible to inhibit tumor 
growth and angiogenesis by using PAMAM dendrimers-
like superfectant associated with 36-mer anionic 
oligomers (ON36) for delivering angiostatin and 
(TIMP)-2 genes. 
Luo et al.
76
 revealed the low cytotoxicity of PEG-
modified PAMAM and their efficiency on the DNA 
delivery. These systems were obtained using low 
generation dendrimers with PEG chains, which mimics 
the fractured high-generation dendrimers. In fact, the 
proposed molecules showed a 20-fold increase in 
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transfection efficiency as compared to that of partially 
degraded dendrimer controls. 
5. Dendrimers in Vaccines Delivery 
Most low molecular weight substances are not 
immunogenic; consequently, when it is desired to raise 
antibodies against small molecules, they must be 
conjugated to a macromolecule. In the past, natural 
proteins have commonly been used as carriers to 
generate antibodies to small molecules; now an 
alternative strategy using dendrimers has been 
demonstrated. In particular, unmodified PAMAM 
dendrimers that fail to elicit an antibody response on 
their own become haptenized upon protein conjugation 
and generate a dendrimer-dependent antigenic response 
77-78
.  
Dendrimers have optimal characteristics to fill the need 
for efficient immunostimulating compounds (adjuvants) 
that can increase the efficiency of vaccines. Also 
dendrimers can provide molecularly defined multivalent 
scaffolds to produce highly defined conjugates with 
small molecule immunostimulators and/or antigens 
79
. 
These molecules are ideal carriers of small antigens, 
making it possible to prepare multimeric antigenic 
conjugates with well-defined molecular properties for 
human uses and they do not induce adverse host 
responses, including immune and/or inflammatory 
reactions upon administration. The interest has focused 
on one specific class of dendrimers, namely, the peptide 
dendrons described in 2005 by Crespo et al. 
80
  
The basic structure described by Tam 
81
 is a dendron 
constructed solely from lysine, taking advantage of the 
two amino groups (R and  ) that are present in each 
lysine molecule and act as branching points for 
logarithmic growth. A two-layer dendron thus has four 
free amino groups and a three-layer dendron has eight, 
equally divided between Rand  -amino groups. Tam 
coined the name “major antigenic peptide” (MAP) for 
such a structure derived from molecules of interest, not 
only limited to peptides, but also any small molecule 
that could bind covalently to the terminal amino groups 
of the MAP “core” dendron. 
6. Dendrimers in Ocular Drug Delivery 
The majorities of topically applied ocular drug-delivery 
systems are formulated either as solutions, ointments, or 
suspensions and suffer from various disadvantages such 
as quick elimination from the precorneal region, poor 
bioavailability, or failure to deliver the drug in a 
sustained fashion. The main challenge in ocular drug 
delivery is to increase the drug bioavailability and 
prolong the residence time of the drug on the cornea, 
conjunctival, and corneal epithelia. Several research 
advances have been made in ocular drug delivery 
systems by using specialized delivery systems such as 
polymers, liposomes, or dendrimers to overcome some 
of these disadvantages. Ideal ocular drug-delivery 
systems should be nonirritating, sterile, isotonic, 
biocompatible, and biodegradable. The viscosity of the 
final product should be optimized so that the dosage 
form does not run out of the eye. Dendrimers provide 
solutions to some complex delivery problems for ocular 
drug delivery.  
Several nanotechnology based carrier systems are being 
developed and studied at large such as nanoparticles, 
liposomes, nanomicelles, nanosuspensions and 
dendrimers. Few of these are commercially 
manufactured at large scale and are applied clinically. 
However, there is still need of developing a carrier 
system which could reach targeted ocular tissue, 
including back of the eye tissues, post non-invasive 
mode of drug administration.  
Tremendous efforts are being put into ocular research 
toward the development of safe and patient compliant 
novel drug delivery strategies.The unique 
nanostructured architecture of dendrimers has been 
studied to examine their role in delivery of therapeutics 
and imaging agents. Dendrimers can increase drug’s 
water solubility, bioavailability, and biocompatibility 
and can be applied for different routes of drug 
administration successfully. 
The first studies on dendrimers for ocular gene delivery 
were conducted in 1999. Chaum et al used the activated 
starburst PAMAM dendrimer SuperFect (Qiagen) as one 
of the transfection agents. The dendrimer consistently 
yielded the highest gene transfer efficiency into primary 
human RPE cells, with the DNA concentration and 
DNA: dendrimer concentration playing a major role in 
the transfection efficiency
82
. 
Other research efforts in dendrimers for ocular drug 
delivery include PAMAM dendrimers that were studied 
by Vandamme and Brobeck as ophthalmic vehicles for 
controlled delivery of pilocarpine and tropicamide to the 
eye 
83
.  
PAMAM dendrimers with carboxylic or hydroxyl 
surface groups, have been reported in improving 
residence time and enhancing bioavailability of 
pilocarpine in the eye.
 84
 In the New Zealand albino 
rabbit model, the residence time of pilocarpine in the 
eye was increased by using dendrimers with carboxylic 
or hydroxyl surface groups. These surface-modified 
dendrimers were predicted to enhance pilocarpine 
bioavailability. 
Shaunak et al. have synthesized water soluble 
conjugates of D(+)-glucosamine and D(+)-glucosamine 
6-sulfate with anionic PAMAM (G3.5) dendrimers to 
obtain synergistic “immunomodulatory and 
antiangiogenic effect. 
85
. These glucosamine and 
glucosamine 6-sulfate dendrimers were studied in a 
rabbit model of scar tissue formation after glaucoma 
filtration surgery. These unique polymeric 
macromolecules increased the long-term success of the 
surgery from 30% to 80% when used together. 
Furthermore, neither microbial infections nor clinical, 
biochemical, or hematological toxicity was observed in 
all animals 
In another study, lipophilic amino-acid dendrimers were 
used to study the long-term effect of use of dendrimer 
for delivery of an antivascular endothelial growth factor 
(VEGF) oligonucleotide (ODN-1) to the eye of rats with 
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the aim of inhibiting laser-induced choroidal 
neovascularization (CNV). It was shown that dendrimer 
containing ODN-1 showed significantly greater 
inhibition of CNV over a 4–6 month period compared 
with ODN-1 alone 
86
. Immunohistochemistry of the eye 
tissue after long-term treatment with dendrimers was 
conducted to determine if an immune response was 
generated after use of the dendrimer as a drug conjugate 
for treating eye diseases. It was determined that there 
was no significant increase in inflammatory response, 
proving that dendrimers could be used as a viable option 
for delivery of oligonucleotide to the eye for treating 
angiogenic eye diseases without concern of generating 
unwanted biological response. 
In a recent study, Puerarin–dendrimer complexes were 
prepared using PAMAM dendrimers (G3.5, G4, G4.5, 
and G5) and their physicochemical properties, in vitro 
release, corneal permeation, and ocular residence times 
were determined. Valia-Chien evaluated the corneal 
permeation and ocular residence time in rabbits using 
diffusion cells with excised corneas. It was reported that 
puerarin-dendrimer complexes exhibited longer 
residence time in rabbit eyes than puerarineyedrops, 
withoutdamage tothe corneal epithelium or endothelium. 
Also results of the in vitro release studies showed that 
puerarin release was much more slower from complexes 
than the free puerarin in PBS. However, corneal 
permeation studies suggested that there was no 
significant difference between puerarin-dendrimer 
complexes and puerarin eye drops on drug permeability 
coefficient 
87
. 
A PAMAM dendrimer hydrogel has been developed by 
Holden and coworkers that is made from “ultraviolet-
cured PAMAMdendrimer” linkedwith PEG-acrylate 
chains for the delivery of two antiglaucoma drugs which 
were brimonidine (0.1% w/v) and timolol maleate (0.5% 
w/v). Dendrimeric hydrogel was obtained by 
crosslinking of the reactive acrylate groups, triggered by 
UV light. It was reported that the dendrimeric hydrogel 
was mucoadhesive and nontoxic to epithelial cells of 
human cornea.Higher uptake from“human corneal 
epithelial cells” and significantly enhanced “bovine 
corneal transport” were reported for both drugs, 
compared to the eye drops. The higher uptake in the 
dendrimeric hydrogel formulations explained the 
temporary decomposition of the corneal epithelial tight 
junctions 
88
. 
In conclusion, they are best suitable drug delivery 
systems with improved bioavailability of drugs, 
increased retention time, reduced side effects, cellular 
targeting, better patient compliance, and providing 
extended therapeutic effects in case of ocular delivery 
7. Dendrimers in Topical and Transdermal delivery 
The ability of transdermal drug delivery systems 
(TDDS) to deliver and maintain a constant therapeutic 
concentration of drug offers a significant potential for 
safe administration of therapeutic agents. TDDS can 
provide a steady drug blood concentration and thus 
avoid peaks and valleys in the drug plasma levels, which 
occur with traditional dosing, such as oral 
administration and intravenous administration. 
Also, sustained/prolonged delivery of therapeutic agents 
in TDDS can simplify the dosing schedule and minimize 
the pain during traditional drug administration.
89
 
Besides, TDDS can improve patient compliance and 
eliminate the hepatic first-pass effect and chemical 
degradation in the gastrointestinal tract.109 
Additionally, patients can choose elsewhere on the skin 
to conduct the TDDS according to their need because 
skin is the largest and most easily accessible organ in 
the body. 
However, transdermal delivery of drugs is limited due to 
the slow rate of transdermal delivery. The outer layer of 
the skin which is served as the first line of defense, is 
composed of closely packed dead cells formed by 
epidermal differentiation and cornification.
90
  
The most common method to improve drug penetration 
through the skin is to use transdermal enhancers. 
Various transdermal enhancers were employed in the 
past two decades. Chemical transdermal enhancers, such 
as organic solvents, are effective because they can 
directly react with the skin, and thus transiently increase 
their permeability but induce immune responses in the 
skin. Therefore, polymeric enhancers with hydrophilic 
and hydrophobic properties have attracted increasing 
interest. PAMAM dendrimers can improve either the 
water-solubility or stability of hydrophobic drugs. These 
materials with hydrophilic outer shells and hydrophobic 
interiors, which accord with structural requirement of 
polymeric transdermal enhancers, are expected to act as 
effective penetration enhancers.  
Wang et al. reported the utilization of 
polyhydroxyalkanoate (PHA) and G3 PAMAM 
dendrimer as a novel TDDS. PHA used in this 
experiment was composed of 3-hydroxyhexanoic acid 
(8%) and 3-hydroxyoctanoic acid (92%)
90
. Before the in 
vitro permeation experiments performed on snake skins, 
PHA and the model drug (tamsulosin hydrochloride) 
were mixed together and laid on the transdermal 
delivery patches. In order to determine the effect of the 
PAMAM dendrimer on in vitro penetration efficiency of 
tamsulosin hydrochloride, they pretreated the snake skin 
with PAMAM dendrimer solution for 24 h. However, no 
significant enhancement of permeation amount of the 
model drug was found. When PAMAM dendrimer was 
coadministrated with the PHA matrix, the penetration 
amount of tamsulosin in the dendrimer-containing PHA 
matrix was 24.0 mg/cm2/day while that in the 
dendrimer-lacking PHA matrix was 15.7 mg/cm2/ day 
(the required amount of this drug in clinical trails is 20 
mg/cm2/day). Thus, the authors concluded that PHA-
dendrimer matrix reached the clinical aim and could be 
developed as a useful delivery system for clinical 
TDDS. 
Dendrimers have found recent applications in novel 
topical and transdermal delivery systems, providing 
benefits such as improved drug solubilization, controlled 
release, and drug-polymer conjugates (pro-drugs). The 
viscosity-generation-number property of a dendrimer 
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solution allows for ease of handling of highly 
concentrated dendrimer formulations for these 
applications. Dendrimers have been shown to be useful 
as transdermal and topical drug delivery systems for 
nonsteroidal anti-inflammatory drugs (NSAIDs), 
antiviral, antimicrobial, anticancer, or antihypertensive 
drugs. PAMAM dendrimers have been studied as carrier 
transdermal systems for the model NSAIDs: ketoprofen 
and diflunisal 
91
. It was found that the PAMAM 
dendrimer-drug formulations showed increased 
transdermal drug delivery compared with formulations 
lacking dendrimers. In vivo studies in mice showed 
prolonged pharmacodynamic responses and 2.73-fold 
higher bioavailability over 24 h for certain dendrimer-
containing drug solutions. 
In another study, transport of indomethacin through 
intact skin was enhanced in vitro and in vivo 
92
. The 
bioavailability of indomethacin was increased by using 
G4-PAMAM dendrimers with terminal amino groups. 
There have also been studies where dendrimers failed to 
show enhancement in drug transport through intact skin. 
It is well known that the molecular diffusion through 
intact skin is related to the molecular weight of the 
permeant molecule. Because of their high molecular 
weights, dendrimers generally have low diffusion 
coefficients. Diffusion through skin is more favorable 
for molecules that have solubility in lipids as well as in 
water. It could be possible to synthesize dendrimers with 
appropriate physical-chemical properties to facilitate 
drug transport through intact skin. Dendrimers with such 
favorable physicochemical properties could enhance 
transdermal transport of drugs by this mechanism. More 
research is warranted in this area to understand the 
structural-activity relationship of dendrimers in relation 
to skin transport. 
In contrast to transdermal delivery, the use of 
dendrimers for topical delivery to the skin has shown to 
be more promising. Two different kinds of dendrimers 
were shown to have antiviral activity in vitro when the 
dendrimers were added to the cells before being 
challenged with the viruses. The dendrimers studied 
were either PAMAM or polylysine dendrimers. In 
contrast, dendrimers added to the cells after they were 
challenged with the virus showed no antiviral activity. 
The study was carried out in an in vitro assay to 
determine dendrimer activity against herpes simplex 
virus (HSV) types 1 and 2. When tested in human 
foreskin fibroblast cells, both PAMAM and polylysine 
dendrimers showed activity against the virus. This study 
suggested that dendrimers could potentially be used as 
topical microbicides to be applied to the vaginal or 
rectal mucosa to protect against sexually transmitted 
diseases such as HIV or genital herpes. When tested 
against genital HSV infection in mice, two of the 
compounds showed significant reduction in infection 
rates when applied prior to intravaginal challenge. 
Dendrimers are able to improve drug properties such as 
solubility and plasma circulation time via transdermal 
formulations and to deliver drugs efficiently due to its 
highly water soluble and biocompatible nature. For 
example improving the drug permeation through the 
skin when PAMAM dendrimer complex with NSAIDs 
like Ketoprofen, Diflunisal and enhanced bioavailability 
of PAMAM dendrimers by using indomethacin as the 
model drug in transdermal drug application
91,92
. 
8. Dendrimers in Pulmonary drug delivery 
The lung is an attractive target for drug delivery due to 
noninvasive systemic delivery via inhalation aerosols, 
avoidance of first-pass metabolism, direct delivery to 
the site of action for the treatment of respiratory 
diseases, and the availability of a huge surface area for 
local drug action and systemic absorption of drug.  
Nanocarrier systems like dendrimers in pulmonary drug 
delivery offer many advantages. These advantages 
include the following:  
1) The potential to achieve relatively uniform 
distribution of drug dose among the alveoli;  
2) An achievement of enhanced solubility of the drug 
than its own aqueous solubility;  
3) The sustained-release of drug which consequently 
reduces the dosing frequency;  
4) Suitability for delivery of macromolecules;  
5) Decreased incidence of side effects;  
6) Improved patient compliance; and  
7) The potential of drug internalization by cells. 
Kukowska-Latallo and colleagues
93
 investigated the 
ability of polyamido amine (PAMAM) dendritic 
polymers (dendrimers) to augment plasmid DNA gene 
transfer in vivo and evaluates the targeting of the lung by 
alternative routes of administration. They suggested that 
vascular administration seemed to achieve expression in 
the lung parenchyma, mainly within the alveoli, while 
endobronchial administration primarily targeted 
bronchial epithelium, indicating that each delivery route 
requires different vectors to achieve optimal transgene 
expression that each approach appears to target different 
cells within the lung. 
Rudolph and colleagues
94
 compared the properties of 
branched polyethylenimine (PEI) 25 kDa and fractured 
PAMAM dendrimers for topical gene transfer to the 
airways in vivo. Their results demonstrated that gene 
transfer mediated by PEI under optimal conditions was 
two orders of magnitude higher compared to fractured 
dendrimers. Therefore, branched PEI 25 kDa was 
superior to fractured dendrimers for gene delivery to the 
airways. 
Polyamidoamine dendrimers with positive charge have 
shown the enhanced bioavailability in pulmonary 
delivery of low-molecular weight heparin (a negatively 
charged oligosaccharide) to treat vascular 
thromboembolism. In this formulation, dendrimer-drug 
complex was formed 
95
. Further studies showed that 
heparin encapsulated in pegylated dendrimers has a 
longer circulating half-time and increased pulmonary 
absorption 
96
. 
Pegylated dendrimeric micelles prolong the half-life of 
low molecular weight heparin (LMWH), Enoxaparin 
and increase the drug’s pulmonary absorption, thereby 
efficacious in preventing deep vein thrombosis (DVT) in 
a rodent model. Shuhua Bai have prepared dendrimers 
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of LMWH entrapped in PEG these produced a 
significant increase in pulmonary absorption and the 
relative bioavailability of the formulation was 60.6% 
compared to subcutaneous LMWH. The half-life of the 
PEG–dendrimer-based formulation was 11.9 h, which is 
2.4-fold greater than the half-life of LMWH in a saline 
control formulation. When the formulation was 
administered at 48-h intervals, the efficacy of LMWH 
encapsulated in pegylated dendrimers in reducing 
thrombus weight in a rodent model was very similar to 
that of subcutaneous LMWH administered at 24-h 
intervals 
97
  
In addition to dendrimers, cationic liposomes were used 
as carriers for heparin and showed enhanced pulmonary 
absorption. These cationic liposomes were prepared by 
conventional methods, i.e. lipid dispersion, solvent 
evaporation and extrusion 
98
. 
9. Dendrimer as Solubility enhancer 
With the discovery of new drug molecules today low 
solubility is the main hurdle to be overcome
99
. 
Approximately 40% of newly developed drugs are 
rejected by the pharmaceutical industry and will never 
benefit a patient because of low water solubility. Given 
the growing impact and need for drug delivery, a 
thorough understanding of delivery technologies that 
enhance the bioavailability of drugs is important. The 
high level of control over the dendritic architecture 
(size, branching density, surface functionality) makes 
dendrimers ideal excipients for enhanced solubility of 
poorly water-soluble drugs. Many commercial small-
molecule drugs with anticancer, anti-inflammatory and 
antimicrobial activity have been formulated successfully 
with dendrimers, such as poly (amidoamine) 
(PAMAM), poly(propylene imine) (PPI or DAB) and 
poly(etherhydroxylamine) (PEHAM). Some dendrimers 
themselves show pharmaceutical activity in these three 
areas, providing the opportunity for combination therapy 
in which the dendrimers serve as the drug carrier and 
simultaneously as an active part of the therapy. 
Dendrimers are unimolecular micellar nature, due to 
have hydrophilic exteriors and hydro-philic interiors and 
form covalent as well as non-covalent complexes with 
drug molecules and hydrophobes, and enhance its 
solubilisation behaviour
100
. 
10. Dendrimers in Cellular delivery  
Medical therapies have become more tailored to specific 
diseases and patients in recent years. Most 
pharmaceutical agents have primary targets within cells 
and tissues; ideally, these agents may be preferentially 
delivered to these sites of action within the cell. 
Selective subcellular delivery is likely to have greater 
therapeutic benefits. Cytosolic delivery, for instance, is 
desirable for drugs that undergo extensive exportation 
from the cell via efflux transporters such as multi-drug 
resistance proteins and P-glycoproteins. These efflux 
mechanisms continuously reduce therapeutic 
intracellular drug concentrations. 
Appropriate surface-functionalized dendrimers can enter 
certain cells remarkably well and, hence, are under 
active investigation aspotential drug delivery and gene-
transfection agents. The objective is to deliver a 
therapeutic drug or gene payload to a specific 
intracellular site for desired local action. The 
intracellular delivery of dendrimer nanocarriers involves 
both extracellular drug release at the interstitium (tissue 
site) and intracellular delivery upon internalization. It is 
essential that the dendrimer nanocarrier loaded with a 
drug or gene is not cleared too quickly from circulation. 
The design of a suitable delivery system requires 
elimination or minimization of all nonspecific 
interactions that might occur between the dendrimer 
vector and the environment of the systemic 
compartment. A primary function of the carrier is to 
mask all unwanted interactions between the drug and the 
environment until the drug is released from the carrier at 
the target site
 19
. 
PAMAM dendrimers with lauryl chains to reduce 
toxicity and enhance cellular uptake, for example 
Dendrimer ibuprofen complexes entered the cells 
rapidly compared with pure drug (1 hr versus>3 hr), 
suggesting that dendrimers can efficiently carry the 
complexes drug inside cells
101
. 
11. Dendrimers as Bio mimetic artificial proteins 
Dendrimers are often referred to as “artificial proteins” 
due to their dimensional length scaling, narrow size 
distribution, and other bio mimetic properties. For 
examples PAMAM family, they closely match the sizes 
and contours of many important proteins and bio 
assemblies like insulin (3 nm), cytochrome C (4 nm), 
and haemoglobin (5.5 nm) are approximately the same 
size and shape as ammonia-core PAMAM dendrimers 
generations 3, 4 and 5, respectively. Generation 2 
dendrimer matches the width (2.4 nm) of DNA duplexes 
(form stable complexes with histone clusters to 
condense and store DNAwithin the nucleosome of 
cells.) and generations 5 and 6 PAMAM dendrimers 
have diameters approximately equivalent to the 
thickness of lipid bilayer membranes (~5.5 nm) of 
biological cells
102, 103
. 
12. Dendrimers as Nano-Drugs 
A number of nano-based systems allow delivery of 
insoluble drugs, allowing the use of previously rejected 
drugs or drugs which are difficult to administer
104
. The 
key useful character of dendrimers is the branches which 
can provide vast amounts of surface area for drugs and 
targeting molecules. Meanwhile, the surface 
functionalities, interior branching, and chemical 
composition of the core play a significant role in 
reactivating the macromolecule. Dendrimer is one of the 
most elegant nanotechnology platform s for targeted 
drug delivery
105
 Conjugated with biotin as the targeting 
moiety; the in vitro targeting ability of partially 
acetylated generation 5 polyamidoamine (PAMAM) 
dendrimer (Ac-G5) in HeLa cells was assessed. The 
multi-functional conjugate Ac-G5-biotin-FITC 
(fluorescein isothiocyanate) showed much higher 
cellular uptake than the conjugate without biotin. The 
energy dependent uptake process can be blocked 
effectively by biotin polymer conjugates, exhibiting an 
expected dose response curve. 
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Dendrimers as Nano-Drugs, useful as antiviral drugs 
against the herpes simplex virus can potentially 
prevent/reduce transmission of HIV and other sexually 
transmitted diseases (STDs) when Poly (lysine) 
dendrimers modified with sulfonated naphthyl groups. 
Show potent antibacterial biocides against Gram 
positive and Gram negative bacteria when PPI 
dendrimers with tertiary alkyl ammonium groups 
attached to the surface and Chitosan– dendrimer hybrids 
have been found to be useful as antibacterial agents, 
carriers in drug delivery systems, and in other 
biomedical applications
84, 106
. 
13. Dendrimers in Site Specific Drug Delivery 
Effective targeted drug delivery systems have been a 
dream for a long time, but it has been largely frustrated 
by the complex chemistry that is involved in the 
development of new systems
107
. The concept of targeted 
drug delivery is designed for attempting to concentrate 
the drug in the tissues of interest while reducing the 
relative concentration of the medication in the remaining 
tissues. As a result, drug is localised on the targeted site. 
Hence, surrounding tissues are not affected by the 
drug
108
. 
The targeted delivery of chemotherapeutics is essential 
to reduce the side effects significantly associated with 
conventional therapy, where healthy tissues such as 
liver, spleen, kidneys and bone marrow can accumulate 
the toxic levels of drug. The site specific delivery of the 
drug could be achieved by surface modification of 
dendrimers employing various targeting moieties such 
as folic acid (FA), peptides, monoclonal antibodies and 
sugar groups.
109
  
Macromolecular delivery of anti-cancer drugs using 
multifunctional dendritic architectures allows for the 
conjugation of both drugs and targeting moieties such as 
folic acid, monoclonal antibodies, and peptides to the 
dendrimer periphery for increasingly specific delivery.   
The two general strategies of targeting include the 
passive targeting of bulk cancerous tissue and the active 
targeting of unique tumor cells. Non-specific or passive 
targeting of tumors is usually achieved by increasing the 
hydrodynamic radius of the dendrimer though 
PEGylation, leading to the accumulation of dendrimer in 
tumor tissue via the enhanced permeability retention 
(EPR) effect. The EPR effect is a result of tumorinduced 
angiogenesis leading to neovasculature that is irregular, 
leaky or defective with disorganized endothelial cells; 
tumor tissues also suffer from poor lymphatic drainage, 
all leading to the accumulation and retention of 
macromolecules in the tumor mass
 110
. Specific or active 
targeting relies on the conjugation of one or more 
targeting moieties to the dendrimer to facilitate cell-
receptor-mediated interactions. 
Several successful active and passive targeting attempts 
were accomplished by engineering the branching units 
and surface groups of dendrimers. Patri et al. conjugated 
FA to G5 PAMAM dendrimer for the targeted delivery 
of methotrexate and observed receptor mediated drug 
delivery that demonstrated high specificity for KB cells 
overexpressing folate receptors and showed slower drug 
release.[35] The authors further conjugated the 
PhiPhiLux G1 D2, an apoptotic sensor to FA attached 
PAMAM dendrimers which showed 5 fold enhanced 
fluorescence, attributed to successful delivery of drug 
with cell‑killing efficacy.111  
pH and temperature-activated polymers are known to be 
successful drug delivery systems. Photochemical 
internalization (PCI) can facilitate site-specific delivery, 
e.g., escape of the macromolecules from endocytic 
vesicles into the cytosol. Lai et al. 
112
 conjugated 
doxorubicin (Dox) to PAMAM dendrimers via pH-
sensitive and insensitive linkers, acid-labile hydrazone 
linkages (PAMAMhyd- Dox) and amide (PAMAM-
amide-Dox), respectively. 
They combined doxorubicin-dendrimers with different 
PCI strategies to evaluate the cytotoxic effects. Results 
showed that both PCI strategies promoted the PAMAM-
amide-Dox cytosolic distribution, but significantly 
enhanced the cytotoxicity of free Dox on human 
gingival cancer (Ca9-22) cells at higher concentrations. 
The authors failed to develop a multi-modality cancer 
treatment, but their data provided insights on possible 
research directions, namely the need to exploit spacers 
other than amide-linkage in drug-polymer complexes. 
Wiwattanapatapee et al. 
113
 investigated the use of 
dendrimers for colon-specific drug delivery 
applications. In their studies, 5-aminosalicylic acid (5-
ASA) was bound to the water-soluble dendrimer using 
different spacers containing azo-bond (e.g., p-
aminobenzoic acid, PABA and p-aminohippuric acid, 
PAH). PAH provide the polymer conjugates a higher 
loading capacity (3 times) for 5-ASA as compared to 
that of dendrimer conjugates with PABA as the spacer. 
In vitro studies of rats with cecal content were carried 
out to investigate drug release from dendrimer 
conjugates. The release of 5-ASA from both conjugates 
was significantly slower as compared to that of 
sulfasalazine (SA), a commercial prodrug. Moreover, 
the conjugate with PAH linker showed significantly 
higher amount of initial drug release than the conjugate 
with the PABA linker. As a consequence, the amount of 
drug released from PAMAM-PAH-SA was significantly 
higher than that of PAMAM-PABA-SA conjugate. This 
study nicely illustrated the potential use of PAMAM 
dendrimer for colon-specific drug delivery, and the 
important role of the spacers for the optimization of 
drug release. 
CD derivatives bearing peptides may be useful as 
carriers for transporting drugs to biological targets 
containing specific peptide receptors. Thus, peptide 
biorecognizability together with the CD host–guest 
complexation properties makes such systems suitable 
templates for the application in site-specific drug 
delivery. Much effort has beenmadeto complex low 
generation dendrimers with other polymers. For 
example, Dodziuk et al. 
114
 reported attempts to complex 
a first-generation dendrimer having four branches with 
α, β or γ cyclodextrins, found to be unsuccessful in their 
subsequentNMRstudies. Muhanna et al. 
115
 reported a 
different strategy, with the synthesis of tetradecavalent 
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amino acid and peptide dendrimers based on a β -CD 
core. These were found to have great potential for 
application in MAP concept as a means to increase the 
peptide–receptor binding, and hence improve the site 
specificity of the drug delivery system.  
14. Dendrimers in Intravenous Drug Delivery: 
The intravenous route is the rapidest and simplest 
method for delivering a drug into the systemic 
circulation.
116
 However, poor water solubility of many 
drugs, especially anti-cancer drugs, limits the 
application of intravenous administration route in 
clinical trails. Intravenous administration of these drugs 
results in several side effects, such as hemolysis and 
phlebitis.
117
  
Much effort has been made to develop new formulations 
that are suitable for the intravenous route, among which 
dendrimer-drug formulation is attracting increasing 
interests as one of the emerging delivery systems. Their 
biodistribution in the body and toxicity or 
immunogenicity must be consider before the proposed 
application of dendrimers in the intravenous route.
118
, 
119
 
Meanwhile, in vivo biodistribution of dendrimers after 
intravenous administration has also been intensively 
studied. Kukowska-Latallo et al.
120
 investigated the 
biodistribution of tritium labeled G5 
PAMAMdendrimers after intravenous administration 
and found these materials were cleared rapidly from the 
blood via the kidney during the first day postinjection. 
Bhadra et al. used G4 PAMAMdendrimer and PEG-
5000 to synthesize PEGylated dendrimers, which were 
applied as potential drug carriers of 5-fluorouracil (5-
FU, an anti-cancer drug). After intravenous 
administration of different formulations of 5-FU 
(equivalent 5-FU in each formulation) to rats through 
the caudal vein, the maximum drug concentration 
(Cmax) from free drugs, nonPEGylated dendrimers, and 
PEGylated dendrimers, was 200–220, 21–23, and 6-7 
mg/mL, respectively
121
. The blood level of 5-FU in 
PEGylated dendrimers formulations was still detectable 
up to 12 h after the drug was administrated. In a 
previous research, Bhadra et al investigated the behavior 
of G4 PAMAM dendrimer/indomethacin complex 
(indomethacin, a nonsteroidal anti-inflammatory drug) 
after intravenous administration.
122
 They obtained 
enhanced effective indomethacin concentrations (2.29 
times) in the inflamed regions with the 
dendrimer/indomethacin complex when compared to the 
free drug in arthritic rats. Although the lymphatic 
drainage existed, intravenous administration of the 
complex still prolonged the retention of the drug at the 
inflamed site. 
FUTURE PROSPECTS 
Dendrimeric polymers are very important and 
convenient for different types of drugs delivery. In order 
to be effective, dendrimer-based products should be 
based on scientific evidence for their usefulness and 
must be easier to translate from laboratory to the clinic, 
in other words be quality-controlable, cost-effective and 
sustainable. 
Literature review of biomedical applications of the 
dendrimers clearly illustrate the potential of this new 
fourth architectural class of polymers and substantiate 
the high optimism for the future of dendrimers in drug 
delivery, diagnosis and therapy. Scientists have explored 
the use of dendrimers for various applications in oral, 
transdermal, ophthalmic, and gene delivery. Although 
dendrimer drug delivery requires attention to certain 
manufacturing and biological considerations to be 
successful. 
Besides drug delivery, dendrimers have been found to 
have a great emphasis in drug delivery through nasal, 
CNS, transdermal, ocular, oral and I.V. route. The use of 
dendrimers in the clinic has still not reached the success 
of linear polymers and several applications remain to be 
explored for its industrial as well as biomedical 
applications. With improved synthesis, further 
understandings of their unique characteristics and 
recognition of new applications, dendrimers will 
become promising candidates for further exploitation in 
drug discovery and clinical applications. Boosting of 
commercial applications of dendrimer technology will 
provide strength for its usefulness in future. 
Targeted delivery is still an active research area for the 
application of dendrimers in CNS drug delivery. Several 
current targets such as LDL receptors, insulin receptor, 
and transferrin receptor have been also found in other 
tissues, suggesting that they are not specific. More 
specific and efficient targets need to be identified to 
facilitate the development of safer and more effective 
dendrimer delivery systems for use in the CNS. 
However, challenges still exist regarding the deeper 
toxicological studies, specific targeting, and noninvasive 
alternative drug administration methods. The ultimate 
goal of dendrimer-mediated drug-delivery systems is to 
engineer the dendrimers to be safe and to enable their 
longterm use without the accumulation of adverse 
effects. 
CONCLUSION 
Dendrimers can work as a useful tool for optimizing 
drug delivery of such problematic drugs. Although the 
application of dendrimers in the field of drug, gene, and 
vaccine delivery is in its infancy, dendrimers offer 
several attractive features, including the control one has 
over the primary nature of the system. They provide a 
platform for the attachment of drugs or genes and their 
release through several mechanisms.  
The high level of control over the architecture of 
dendrimer, their shape, branching length and density, 
their surface functionality and interior void space 
(porosity) and so on makes dendrimer ideal carriers for 
the various applications like drug delivery, therapeutic 
and diagnostic agent. Poor solubility, bioavailability and 
permeability biocompatibility and toxicity can be 
overcome by use it. 
PEGylation of the dendrimer surface can prolong its 
circulation time and reduce its toxicity. BBB- or CNS-
targeting ligand modification of the dendrimer surface 
can improve the rate and duration of drug delivery to 
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brain tumor cells prior to the clearance of the remaining 
drug-delivery system. 
Hopefully, this review of dendrimer-based medical 
applications clearly illustrates the potential application 
of this new ‘fourth architectural class of polymers’ and 
reaffirms an even higher level of optimism for the future 
role of dendrimers in the drug delivery. With continued 
research and development efforts, dendrimer is expected 
to have a tremendous impact on delivery of drugs in 
future. 
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Abbreviations: 2-AS, 12-(9-anthroyloxy) stearic acid; 2-D, two-dimensional; 3-D, three-dimensional; 3-TC, lamivudine; Ac, acetylated; 
AChE, acetylcholinesterase; AF, alexaFluor; AFM, atomic force microscopy; ATRP, atom transfer radical polymerization; b-FGF, basic 
fibroblast growth factor; BAPTA-AM, 1,2-bis-(o-aminophenoxy) ethane-N,N,N’,N’,-tetraacetic acid-acetoxymethyl ester; BMVEC, brain 
micro-vessel endothelial cells; BNTC, boron neutron capture therapy; CLB, chlorambucil; CED, convection enhanced delivery; CMCht, 
carboxymethylchitosan; CMCht/PAMAM, carboxymethylchitosan/poly (amidoamine); DCC, dicyclohexylcarbodiimide; Dex, 
dexamethasone; di-BOC, di-tert-butyl dicarbonate; DOTAP, N-(1-(2,3-dio-leoyloxy) propyl)-N,N,N-trimethyl ammonium methylsulfate; 
EBV, Epstein Barr virus; ECM, extracellular matrix; EGF, epidermal growth factor; EGFP, green fluorescent protein; ENFET, enzyme 
field-effect transistor; EPR, electron paramagnetic resonance; FA, folic acid; FITC, fluorescein isothiocyanate; G, generation number; 
GAGs, glycosaminoglycans; GLUT 1, glucose transporter; GOX, glucose oxidase; HA, Hyaluronic acid; HAp, hydroxyapatite; HAS, human 
serum albumin; HBP, hyperbranched polymer; HER-2, human growth receptor; HMGB1, high mobility group box 1 plasmid; HSGP, 
heparin or heparan sulfate proteoglycan; i.p., intraperitoneal; i.t., intratumoral; LCST, lower critical solution temperature; LH, light-
harvesting; MA, methacrylate; MAPs, multiple antigen peptides; Man, mannose; Mn, number-average molecular weight; Mo/Mac, 
monocyte/macrophages; MPPI, poly(propyleneimine); MRI, magnetic resonance imaging; MS, multiple sclerosis; Mw,weight-average 
molecular weight,Mw/Mn polydispersity index; NaHA, sodium hyaluronate;NMR,nuclear magnetic resonance; OEI, oligoethylenimine; 
OG, oregon green; ONs, antisense oligonucleotides; PAMAM, poly(amidoamine); PAH, p-aminohippuric acid; PCI, photochemical-
internalization; PDMA, poly(N,N-dimethylaminoethyl methacrylate); PEG-DA, poly(ethylene glycol)-dialdehyde; PEI, 
poly(ethyleneimine); PEPE, polyether-copolyester; PETIM, poly(propyl ether imine); PLGSA, poly(glycerol-succinic acid); PLL, poly-(l-
lysine); PNIPAAM, poly(N-isopropylacrylamide); PP, primaquine phosphate; PPI, poly(propyleneimine); PrPSc, protease-resistant isoform 
of the prion protein; PSMA, prostrate specific membrane antigen; PTX, paclitaxel; RAFT, reversible addition-fragmentation transfer; RGD, 
Arg-Gly-Asp peptides; ROS, reactive oxygen species; SA, sulfasalazine; SEM, scanning electron microscopy; shRNA, small hairpin RNA; 
t-BOC, N-tert-butoxycarbonyl; TE, tissue engineering; ThT, thioflavin T; TIMP, tissue inhibitors of metalloproteinases; TMA-DPH, 1 
(trimethylammoniumphenyl)-6-phenyl-1,3,5 hexatriene p-toluenesulfonate; VEGF, vascular endothelial growth factor. 
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